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Abstract
Introduction:

Asymptomatic

and

mildly

symptomatic

dominantly

inherited

Alzheimer’s disease mutation carriers (DIAD-MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain
atrophy is an early feature of DIAD-MC and could help predict risk for dementia
during trial enrollment.
Methods: We created a dementia risk score by entering standardized gray-matter volumes from 231 DIAD-MC into a logistic regression to classify participants with and
without dementia. The score’s predictive utility was assessed using Cox models and
receiver operating curves on a separate group of 65 DIAD-MC followed longitudinally.
Results: Our risk score separated asymptomatic versus demented DIAD-MC with
96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under
the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset.
Discussion: Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD-MC participants for prevention trials.
KEYWORDS

autosomal dominant Alzheimer’s disease, brain atrophy, Dominantly Inherited Alzheimer Network, preclinical Alzheimer’s disease
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1

INTRODUCTION
HIGHLIGHTS

Alzheimer’s disease (AD) is a devastating progressive neurodegener-

∙ Brain atrophy precedes cognitive decline by years in dom-

ative disease with high worldwide prevalence. Recent drug trials for

inantly inherited Alzheimer’s disease.
∙ Brain atrophy–based risk scores can predict dementia

patients with dementia and underlying AD have failed to show meaningful

benefit.1,2

One potential explanation for the failure to demon-

onset in mutation carriers.
∙ Risk score can help establish enrollment criteria for

strate efficacy is that the interventions were given at disease stages
that are too late to alter clinical

progression.3

Many ongoing trials are

Alzheimer’s disease prevention trials.

attempting treatment at an earlier stage, such as at the time of mild
cognitive symptoms or before the onset of cognitive

symptoms.4,5

To

evaluate the ability of these interventions to prevent development of
dementia, researchers need to recruit individuals with a very high risk
of developing symptoms of dementia over the duration of a clinical trial
(usually 1 or 2 years).3 Carriers of mutations in genes that cause dom-

rent study was to evaluate whether a similar method is useful in DIAD

inantly inherited AD (DIAD), such as presenilin-1 (PSEN1), presenilin-2

and to assess its added benefit beyond the estimated years to onset

(PSEN2), and amyloid precursor protein (APP), are certain to develop

(EYO) that is calculated based on the reported age of onset for each

dementia, and thus are ideal candidates for AD prevention studies.

specific DIAD mutation.

Nearly all DIAD mutation carriers (DIAD-MC) develop dementia.
Although the time until the onset of dementia can be estimated based
on the age of symptom onset from individuals with the same type of

2

METHODS

muation,6 variability of several years is frequently observed, and this
can occur even within the same family.7

2.1

Overview

Another approach for approximating time to symptom onset is to
use established biological markers of disease (biomarkers). Similar to

Our analysis was conducted in two stages. The first stage used logistic

sporadic AD, DIAD-MC undergo biological changes years before the

regression in cognitively normal DIAD-MC participants and DIAD-MC

onset of dementia.8,9 Such changes can be measured with magnetic

patients with established dementia at study entry to identify a pattern

resonance imaging (MRI);6,8,10–17 cerebrospinal fluid (CSF) levels of

of atrophy associated with the presence of dementia and to develop a

amyloid beta (Aβ) and phosphorylated tau and total tau;6,8,12,18 and

dementia risk score that can be calculated based on the similarity of

positron emission tomography (PET) radiotracers that measure glu-

a given individual’s regional brain volumes to that pattern. In the sec-

cose metabolism,6,8,12 Aβ6,12 fibrils, and tau accumulation.19 Indeed,

ond stage of the analysis, the risk score was applied to DIAD-MC par-

previous studies have shown that changes in many of these biomark-

ticipants who had not yet developed dementia at study entry and who

ers precede cognitive decline in DIAD-MC.12 Some of the aforemen-

were followed longitudinally, and the ability of the risk score to predict

tioned imaging modalities are expensive, involve exposure to ionizing

onset of dementia at follow-up was assessed.

radiation, and are relatively scarce in many parts of the world. It is
thus encouraging that baseline hippocampal volume and change in hippocampal volume over time, which can be measured from MRI, are both

2.2

Subjects

predictive of decline in DIAD-MC.12 Changes in volume in other brain
regions are also predictive of cognitive decline in DIAD-MC.10,14 This

We included 216 DIAD-MC enrolled in the Dominantly Inherited

would be expected given that cognition is dependent on many brain

Alzheimer Network (DIAN; 12th data freeze, 2008 to 2017), and 15

regions and that AD characteristically spreads through the brain as dis-

DIAD-MC seen at the Alzheimer’s Disease Research Centers at the

ease advances.20 Prior studies in sporadic AD have indicated that mea-

University of California Los Angeles (ADRC-UCLA) and University of

surements of volume across the brain can predict likelihood of devel-

Southern California (ADRC-USC), as well as 99 non-carrier family

oping dementia.21,22 Together, these findings suggest that quantifica-

members enrolled in DIAN as controls for image analysis. We included

tion of volume loss across the brain might provide a good predictor of

the additional ADRC cohort patients because the DIAN dataset con-

time to onset of dementia. If such an estimate could be derived from a

tained relatively few cases who had established dementia at study

single measurement, it would further improve its value, for instance by

entry.

allowing people who appear far from dementia to defer follow-up for a
longer period compared to those in whom dementia is imminent.

DIAN is a multicenter study of individuals from families with known
causative mutations for DIAD. Enrolled family members undergo

Individualized atrophy-based risk scores have been previously

initial genotyping and clinical reassessment every one or more years,

reported to predict symptom onset in asymptomatic carriers of muta-

including neuroimaging. Subjects can be DIAD-MC or non-carrier fam-

tions that cause frontotemporal dementia.23 The risk score uses calcu-

ily members. The DIAN study receives approval from the institutional

lated atrophy in each brain region at a single time point to predict the

review board (IRB) of each participating site. Written informed con-

individual’s risk for dementia at subsequent visits. The aim of the cur-

sent is obtained from all participants or their designated guardians.8
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TA B L E 1

Participant demographics and genotype (of three mutated genes causing dominantly inherited Alzheimer’s disease)
Control group
CDR 0

Cohort

DIAN

N (visits)
Follow up Mean ± SD (years)

Training group
CDR 0

Testing group

CDR≥ 1

DIAN

b

DIAN

ADRC

CDR 0

CDR 0.5

Convertersa

DIAN

DIAN

DIAN

99 (99)

123 (123)

28 (28)

15 (15)

15 (54)

20 (57)

30 (95)

2.9 ± 3.4

2.79 ± 1.09

1.56 ± 1.36

NA

5.01 ± 1.23

3.15 ± 1.52

2.39 ± 1.35

PSEN1

NA

87

22

15

11

13

21

PSEN2

NA

15

0

0

0

0

3

APP

NA

21

6

0

4

7

6

Age Mean ± SD (years)

38 ± 11.3

33.6 ± 9.5

48.7 ± 8.8

43 ± 6.1

39.2 ± 9.8

47.2 ± 10.7

43.2 ± 9.0

Male %

41 (41%)

56 (45.5%)

14 (50%)

9 (60.0%)

4 (26.6%)

5 (25%)

11 (36.6%)

Abbreviations: ADRC, Alzheimer’s Disease Research Center; APP, amyloid precursor protein; CDR, Clinical Dementia Rating; DIAN, Dominantly Inherited
Alzheimer Network; PSEN, presenilin; SD, standard deviation; UCLA, University of California Los Angeles; USC, University of Southern California.
a
Refers to subjects from the ADRC-UCLA and ARDC-USC.
b
Converters refers to subject who converted from CDR 0 or from CDR 0.5 to CDR 1, 2, or 3, and to subjects who converted from CDR 0 to CDR 0.5.

The ADRC-UCLA and ADRC-USC are both National Institute on

age from the mean age of symptom onset for their specific mutation7

Aging–designated research centers that offer extensive clinical, neu-

(i.e., negative values indicate conversion is expected to occur in the

roimaging, and molecular profiling of patients with dementia, including

future).

DIAD-MC.24 In the case of DIAD-MC evaluated in ADRC-UCLA or
ADRC-USC, the study was approved by each institution’s IRB. Subjects
or their proxies gave written approval for study participation.13

2.4

Image acquisition

Our inclusion criteria included availability of the following data for
each individual: age, sex, and functional status data as expressed in

Participants in the DIAN study underwent 3-Tesla volumetric T1-

Clinical Dementia Rating Global Score (henceforth referred to as CDR),

weighted MRI according to the Alzheimer’s Disease Neuroimaging Ini-

and one or more 3-Tesla T1 structural MRIs.

tiative (ADNI)–defined sequences.25 Matching between scanners and

The 231 DIAD-MC were divided into two groups. A training group

image quality control were performed according to the ADNI proto-

(n = 166) was created to identify the atrophy pattern associated with

col by the study imaging core.8 Participants of the ADRC-UCLA and

dementia and develop a dementia risk score. This group consisted

ADRC-USC underwent similar MRI acquisition protocols (see Table S1

of 123 participants with CDR = 0 and 43 patients with CDR ≥1 at

in supporting information).

their first visit. To maximize the likelihood that the images from the
CDR = 0 group represented the asymptomatic phase of disease, we
only included individuals with a CDR = 0 rating for two consecutive vis-

2.5

Image processing

its. The first study image from each participant was used for training.
The testing group consisted of 65 DIAD-MC who did not have demen-

For this study we only analyzed T1-weighted images. We excluded all

tia at study entry and who were followed longitudinally, and whose

images with excessive motion and imaging artifacts, as determined by

images were used to test the risk score. Table 1 summarizes the groups

visual inspection. We corrected for magnetic field bias using the N3

and the amount of DIAD-MC in each.

algorithm.26 We segmented the remaining images using the unified
segmentation procedure in Statistical Parametric Mapping (SPM) version 12 into gray matter (GM), white matter, and CSF.27

2.3

Clinical and genetic assessment

The next steps in image processing depended on whether the participant contributed an image from a single observation or multiple longi-

Functional status was determined using the CDR. Each individual’s

tudinal observations. For the training group, a study-specific template

CDR represents a weighted average of six functional domains (mem-

representative of all participants was generated from T1 GM images

ory, orientation, judgment and problem solving, community affairs,

using diffeomorphic anatomical registration using exponentiated lie

home and hobbies, personal care). The scale categorizes individuals as

algebra.28 The images were subsequently normalized and modulated in

asymptomatic (CDR = 0), having very mild symptoms that do not impair

the study-specific template space using linear and non-linear registra-

independent functioning (CDR = 0.5), or clear symptoms of dementia

tion.

(CDR ≥ 1). Genotyping methods have been previously described.8,13

For the testing group, an additional step included creation of an

The mutation-EYO is a variable that estimates the time until symp-

intraparticipant template using nonlinear diffeomorphic and rigid body

tom onset and is calculated at each visit by subtracting the participant’s

registration implemented with SPM.29 This process minimizes bias in

5 of 11

KERET ET AL.

estimating change in volume over time.27 The group template for this

which included carriers who started at a CDR 0 or 0.5 and were fol-

group was generated from the within-participant averaged GM, white

lowed longitudinally.

matter, and CSF tissue maps by nonlinear and rigid-body registration.

We used a Cox regression model with atrophy risk score and

All images were then warped into a group template space and

mutation-EYO as time-varying predictors and conversion from

smoothed with a 4 mm isotropic Gaussian kernel. We calculated total

CDR = 0 or CDR = 0.5 to CDR ≥ 1 as the outcome. Sex was added

intracranial volume (TIV) for each participant in group template space.

as a covariate in these models. To quantify the relationship between
risk score and outcome, we estimated the effect of a 10% increase in
the risk score (increase in value of 0.1). A Kaplan–Meier curve was

2.6

Calculation of atrophy burden

constructed for this model with individual scores dichotomized above
and below risk score value 0.5; this value was chosen for illustra-

For every processed image, we estimated atrophy in each GM voxel by

tive purposes. We also tested an interaction effect of risk score by

regional voxel estimates of volume relative to a control group of 99

mutation-EYO in a second model.

non-carrier asymptomatic family members from the DIAN study. This

In addition, we evaluated and compared the risk scores and

was done to create a W-score, which is similar to a z-score and repre-

mutation-EYO performance in identifying DIAD-MC who converted

sents a standardized estimate of atrophy at that voxel after account-

from either CDR 0 or 0.5 to CDR ≥ 1 within 25 months of their base-

ing for age and TIV.30 We summed the voxel-wise W-scores within 179

line visit using a ROC curve. This time frame was chosen to approxi-

regions of interest (ROI), as defined by the Desikan brain atlas31 to cre-

mate duration of some disease-modifying drug trials that might target

ate a measure of atrophy burden for each ROI.

prevention of dementia. For this analysis, we included the same individuals as in the Cox regression model. We dichotomized the risk scores
above 0.5 and the mutation-EYO value higher than negative 25 months

2.7
Generation of DIAD atrophy-based dementia
risk score

as predicting change from CDR = 0 or 0.5 to CDR ≥ 1. This technique
fits a maximum likelihood ROC model using a binormal distribution of
the true state of the observation (progressed vs. not progressed). The

The concept and method for generating an atrophy-based dementia

ROC models were fitted using Stata v16.1.

risk score (henceforth risk score) from w-scores has been described
in detail previously.23 Briefly, we created w-score based regional measures of atrophy burden, as described above, from the earliest images

3

RESULTS

obtained from individuals in the training group. The regional atrophy
burden estimates from the asymptomatic and CDR ≥ 1 cases in the

3.1

Participants

training group were entered into an L2-regularized logistic regression algorithm,32 with diagnosis as the categorical outcome. The algo-

The study group included 231 DIAD-MC and 99 non-carrier family

rithm was implemented in a machine learning Python package using

members. Of these, 166 DIAD-MC were included in the training group

the fast incremental gradient method.33,34 The probability distribu-

for generating the logistic model risk score (124 PSEN1, 15 PSEN2, and

tion formula and method of optimizing the empirical log-logistic have

27 APP) and 65 in the testing group for survival analysis (45 PSEN1, 3

been previously described.23 To estimate model performance a five-

PSEN2, and 17 APP). Table 1 summarizes the age and sex by symptom

fold cross-validation scheme was used,35 as previously described.23

severity for each analysis used, including the control group.

The predicted outcome from the fitted logistic regression equation is
a risk score that ranges from 0 to 1 and represents the probability
of either being demented or asymptomatic. To test the accuracy of
our risk in separating asymptomatic from DIAD-MC with dementia we

3.2
Atrophy-based dementia risk score
generation

dichotomized individual scores above 0.5 as approximating dementia
and below 0.5 approximating asymptomatic individuals. We compared

The training group consisted of 43 DIAD-MC with CDR ≥ 1 and 123

risk score–based approximation of symptoms to actual symptoms in

with CDR = 0 for two consecutive visits, and a mean time on CDR = 0 of

each individual. The risk score accuracy was calculated as the propor-

2.79 ± 1.09 years. Figure 1 shows the optimal weight each brain region

tion of patients correctly classified.

is given as a covariate in the logistic regression formula for the risk
score. An ROI’s weight indicates its reliability in separating CDR = 0
and CDR ≥ 1. Table 2 lists the 50 ROIs with highest absolute weight

2.8

Testing the utility of the risk score

alongside their mean standardized atrophy in DIAD-MC with CDR ≥
1. As expected, subregions of the medial temporal, precuneus, tem-

We next assessed the utility of the risk score and mutation-EYO for

poroparietal, and dorsolateral frontal regions comprised most of the

predicting dementia onset in the testing group using two methods: a

list and showed the largest degree of atrophy, but high weights for pre-

Cox regression model and a receiver operating characteristic (ROC)

diction were also observed in subcortical regions such as the cerebellar

curve. Risk scores were calculated from all images in the testing group,

cortices, globus pallidi, and caudate nuclei. Our model achieved good
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F I G U R E 1 Brain map displaying the relative weight (color coded) each region of interest (ROI) is given in the atrophy-based dementia risk
score. Individual ROI weights were the result of the optimization of the logistic regression model. These weights were subsequently used to
calculate prediction scores for the survival analysis. The weight indicates the degree of reliability of an ROI in separating presymptomatic and
demented dominantly inherited Alzheimer’s disease mutation carriers. An ROI with a high positive or negative weight increases the probability
that a given individual with atrophy in this region is Clinical Dementia Rating (CDR) scale ≥ 1 or CDR = 0 respectively, whereas a weight closer to
zero or zero indicates the ROI is less relevant for separating between these two outcomes. A and D, Left lateral and medial views, respectively. C
and F, Right lateral and medial views, respectively. B and E, Hippocampal and basal ganglia level coronal slices, respectively

separation of symptomatic DIAD-MC based on risk score cutoff above
0.5 with a 96.4% (standard error [SE] = 0.02).

3.3

Predicting symptom onset

The hazard ratio (HR) for our Cox model was 1.31 (95% confidence
interval [CI] 1.14–1.49, P < .001), indicating higher risk and shorter
time to conversion with increasing risk score. Results of Kaplan–Meier
curve for the Cox model, after dichotomizing the risk score using a
threshold of 0.5, can be seen in Figure 2. The HR for mutation-EYO
was 1.18 (95% CI 1.03–1.35, P = .017). Sex was not a statistically significant predictor of survival (HR = 0.41, 95% CI 0.15–1.16, P = .093),
but was in the direction of greater risk for males. There was no significant interaction between mutation-EYO and risk score (P = .88). The
ROC area under the curve (AUC) was 0.903 (0.823–0.982) for the risk
score, 0.825 (0.724–0.927) for the EYO, and 0.910 (0.830–0.990) for
both (Figure 3).

4

F I G U R E 2 Kaplan–Meier curve of displaying dominantly inherited
Alzheimer’s disease mutation carriers survival from Clinical Dementia
Rating (CDR) scale 0 or 0.5 to CDR 1. Mutation carriers were
dichotomized using the atrophy-based dementia risk score values
above and below 0.5 (red and blue, respectively)

DISCUSSION
likelihood of converting to dementia. Last, the risk score was useful in

Our aim was to determine whether individualized atrophy-based risk

identifying asymptomatic DIAD-MC that converted to dementia within

scores from a single observation could predict onset of dementia in

2 years with 90.3% accuracy, and achieved 91% accuracy when com-

DIAD-MC. Our developed risk score separated asymptomatic DIAD-

bined with the EYO.

MC from those with dementia with an accuracy of 96.4%. Moreover,

These findings are consistent with and extend prior work. In particu-

in an independent subset of asymptomatic and mildly symptomatic

lar, previous studies have shown that hippocampal volumes and decline

DIAD-MC with longitudinal observations, every 0.1 unit increase in

in hippocampal and whole brain cortical volumes, as well as other

our risk score (a 10% increase) translated to roughly 1.3-fold increased

biomarkers, predict decline in DIAD-MC.6,8,10–13,36 To our knowledge
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this is the first study demonstrating the utility of single measurements

tia without reliance on a priori ROI. Indeed, although our analysis

of cerebral GM for predicting dementia onset, a critical event in the

showed that the temporal, parietal, and frontal regions showed the

evolution of disease, in DIAD-MC.

highest degree of atrophy and predicted onset of dementia, as would

Our results suggest that individualized atrophy-based dementia risk

be expected based on sporadic AD (Figure 1, Table 2), regions not typ-

scores could help address several challenges in developing treatments

ically atrophic in sporadic AD, such as the cerebellar cortices, globus

for AD. The age of symptom onset can vary by many years in DIAD-MC

pallidi, and caudate nuclei also contributed to prediction. The highest

even within carriers of the same type of DIAD mutation.7 Trials seek-

contribution of atypical ROI was from the cerebellar cortices, although

ing to delay dementia onset must identify individuals that will develop

it should be noted that the combined contributions of atypical subcor-

symptoms within a short, defined time frame. An atrophy-based risk

tical regions was smaller than for the typical AD regions taken together.

score may be useful for selecting mutation carriers that are closest to

While cerebellar GM volume in DIAD-MC with dementia was reliably

dementia conversion. This can help avoid unnecessary inclusion of indi-

lower than that of asymptomatic DIAD-MC, regions typical of sporadic

viduals at low risk for dementia within 2 to 3 years in studies of DIAD-

AD were on average more atrophic and together contributed more to

MC and increase trial power. Moreover, individual atrophy maps and

the risk score (Table 2). Cerebellar atrophy is generally understudied

risk scores can theoretically be used to follow recruited subjects for

in AD and DIAD. It has been previously described in some studies of

progression throughout trials. Proximity to dementia onset may also be

DIAD-MC,10,16,41 but many studies have relied on surface-based meth-

used to inform clinical care of DIAD-MC.

ods that exclude the cerebellum from analysis.14,15

Our approach is similar to prior analyses that used baseline atrophy
patterns to predict dementia in sporadic

AD.22,37

Our current methods have several limitations that could be

Many of these stud-

addressed in future analyses to improve utility. Accuracy of the risk

ies were conducted using data from the ADNI.22,38,39 This database

score can be increased by using a larger sample size. To generate

comprises individuals with sporadic AD that are on average 30 to

our risk score we pooled three different DIAD genes (with 67 dif-

40 years older than most DIAD-MC. Brain atrophy in DIAD-MC can

ferent mutations) to maximize our sample size. Building this model

occur in areas not typically associated with sporadic AD, such as the

in each gene separately would likely increase risk score accuracy but

thalamus.10

Thus, models relying on atrophy in sporadic

would require a larger sample size. Furthermore, the relative value

AD, particularly in predetermined ROI,21,38,40 might not be generaliz-

of imaging-based predictors compared to mutation-EYO may vary by

able to DIAD populations. This justified an empirical approach to iden-

mutation. The risk score was generated from neuroimaging data of 43

tify the most valuable regions for predicting dementia in DIAD. Our

DIAD-MC with dementia; of these 12 had a CDR of 2 or 3. Using neu-

method is designed to identify regions that predict onset of demen-

roimaging data from DIAD carriers at earliest conversion to CDR of

putamen and
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TA B L E 2 The 50 ROI of highest absolute weight given in the
atrophy-based dementia risk score alongside the ROI’s mean
standardized atrophy (W-score) in DIAD-MC with CDR >1

Gray matter regions of interest
(Desikan-Killiany Atlas)

Weight

W-scores
in CDR ≥ 1
(mean ± SD)

Caudal middle frontal left

0.5747

–0.79 ± 0.58

Cerebellum left

0.5111

–0.61 ± 1.14

Inferior temporal right

0.4847

–1.07 ± 0.64

Banks superior temporal sulcus left

0.4803

–1.39 ± 0.8

Caudal middle frontal right

0.44

–0.69 ± 0.64

Entorhinal right

0.3732

–1.22 ± 1.14

Pallidum right

0.3643

–0.17 ± 0.12

Inferior parietal right

0.3557

–1.26 ± 0.72

Precuneus right

0.3466

–1.6 ± 0.68

Middle temporal right

0.3432

–1.29 ± 0.79

Cerebellum right

0.3356

–0.6 ± 1.02

Caudal anterior cingulate right

0.3228

–0.74 ± 0.81

Precuneus left

0.3012

–1.57 ± 0.66

Pars oercularis left

0.298

–0.67 ± 0.66

Insula left

0.2961

–0.84 ± 0.79

Pallidum left

0.2933

–0.29 ± 0.19

TA B L E 2

(Continued)

Gray matter regions of interest
(Desikan-Killiany Atlas)

Weight

W-scores
in CDR ≥ 1
(mean ± SD)

Rostral anterior cingulate left

0.1414

–0.77 ± 0.76

Inferior temporal

-0.143

–1.04 ± 0.71

Putamen right

-0.1533

–1.56 ± 1.12

Frontal pole left

-0.1601

–0.64 ± 0.81

Ventral diencephalon right

-0.1868

–0.49 ± 0.4

Thalamus right

-0.2259

–1.23 ± 0.83

Postcentral left

-0.2306

–1.06 ± 0.71

Postcentral right

-0.251

–1.28 ± 0.78

Medial orbital frontal right

-0.2833

–0.73 ± 0.82

Abbreviations: CDR, Clinical Dementia Rating; DIAD-MC, dominantly
inherited Alzheimer’s disease mutation carrier; ROI, region of interest; SD,
standard deviation.
Notes: Individual ROI weights were the result of the optimization of the
logistic regression model. The weight indicates the degree of reliability of
an ROI in separating presymptomatic and demented DIAD mutation carriers and does not necessarily correlate with the degree of atrophy.
An ROI with a high positive or negative weight increases the probability that
a given individual with atrophy in this region is CDR ≥ 1 or CDR = 0, respectively, whereas a weight closer to zero or zero indicates the ROI is less relevant for separating these two outcomes.

Hippocampus right

0.2859

–1.8 ± 1.22

Inferior parietal left

0.2593

–1.18 ± 0.71

one might improve the sensitivity of this risk score. Another limita-

Superior parietal right

0.2573

–1.02 ± 0.51

tion is the use of dementia as a binary outcome, and future trials

Rostral middle frontal right

0.2422

–0.74 ± 0.65

may use time to reach an earlier, cognitively defined threshold. Nev-

Paracentral right

0.2267

–1.09 ± 0.81

ertheless, cognitive impairment as defined by CDR is still the major

Pars opercularis right

0.2245

–0.58 ± 0.71

outcome in most AD clinical trials. Last, while T1-weighted MRI and

Supramarginal left

0.2237

–1.3 ± 0.82

EYO already provide a high degree of accuracy, other neuroimaging

Lateral orbital frontal left

0.2145

–0.6 ± 0.77

Lateral occipital left

0.2127

–1.29 ± 0.62

Lingual left

0.2106

–1.27 ± 0.77

into a powerful tool for clinical trials and may also facilitate treatment

measures,6,8,41,42,10–16,19 biochemical,6,8,12,18,43 or other markers of
AD44 can potentially be added to the model to improve accuracy.
With all of these enhancements, prediction scores can be developed

Insula right

0.2096

–0.94 ± 0.91

planning in DIAD-MC and other people with high risk for developing

Superior temporal left

0.2081

–1.17 ± 0.78

dementia.

Cuneus left

0.2072

–1.44 ± 0.78

Caudate left

0.2061

–0.73 ± 0.94
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